CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P26
Within normal range
vs 5Y Ago
-1.7x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -49.49% |
| Q3 2025 | 1.30% |
| Q2 2025 | 25.14% |
| Q1 2025 | -5.70% |
| Q4 2024 | 3.96% |
| Q3 2024 | -6.04% |
| Q2 2024 | 24.94% |
| Q1 2024 | -18.59% |
| Q4 2023 | -20.39% |
| Q3 2023 | 27.54% |
| Q2 2023 | -369.31% |
| Q1 2023 | 770.66% |
| Q4 2022 | 95.88% |
| Q3 2022 | 1.15% |
| Q2 2022 | 17.13% |
| Q1 2022 | -32.45% |
| Q4 2021 | -5.02% |
| Q3 2021 | -5.32% |
| Q2 2021 | 5.81% |
| Q1 2021 | -71.80% |
| Q4 2020 | 29.38% |
| Q3 2020 | -125.41% |
| Q2 2020 | 295.23% |
| Q1 2020 | -68.72% |
| Q4 2019 | -26.42% |
| Q3 2019 | 52.07% |
| Q2 2019 | -24.66% |
| Q1 2019 | -35.79% |
| Q4 2018 | -417.78% |
| Q3 2018 | 79.14% |
| Q2 2018 | -82.15% |
| Q1 2018 | -166.41% |
| Q4 2017 | 483.44% |
| Q3 2017 | -103.31% |
| Q2 2017 | 1007.45% |
| Q1 2017 | -1085.85% |
| Q4 2016 | 113.65% |
| Q3 2016 | -190.02% |
| Q2 2016 | 384.37% |
| Q1 2016 | 32.18% |